GSK plc (the 'Company')
Transaction notification
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Dr Hal Barron |
|||
b) |
Position/status |
Non-Executive Director |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs')
ISIN: US37733W2044 |
|||
b) |
Nature of the transaction |
Acquisition of notional ADSs within Dr Barron's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends
|
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
$36.6400 |
3,269.946 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2025-02-21 |
|||
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Dr Hal Barron |
|||
b) |
Position/status |
Non-Executive Director |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs')
ISIN: US37733W2044 |
|||
b) |
Nature of the transaction |
Acquisition of ADSs within Dr Barron's GSK 401(k) plan account following the reinvestment of dividends |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
$36.6400 |
83 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2025-02-21 |
|||
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
James Ford |
|||
b) |
Position/status |
SVP and Group General Counsel, Legal and Compliance |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs')
ISIN: US37733W2044 |
|||
b) |
Nature of the transaction |
Acquisition of notional ADSs within Mr Ford's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends
|
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
$36.6400 |
60.846 |
|
||
|
|
|
|
||
d) |
Aggregated information |
N/A (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2025-02-21 |
|||
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
James Ford |
|||
b) |
Position/status |
SVP and Group General Counsel, Legal and Compliance |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
|||
b) |
Nature of the transaction |
Sale of 10,400 Ordinary Shares |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£14.5541
|
10,400 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2025-02-25 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Emma Walmsley |
|||
b) |
Position/status |
Chief Executive Officer |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
b) |
Nature of the transaction |
Gift of ordinary shares to family member for nil consideration |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£0.00 |
123,700 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2025-02-21 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |